DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CEFPROZIL

« Back to Dashboard

All Clinical Trials for Cefprozil

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00778245	Bioequivalence Study of Cefprozil Tablets, USP 500 mg Undef Fed Conditions	Completed	Ranbaxy Laboratories Limited	N/A	2005-05-01	The objective of this study is to assess the single - dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fed conditions.
NCT00778557	Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fasting Conditions	Completed	Ranbaxy Laboratories Limited	N/A	2005-06-01	The study was conducted as a blinded, randomized, 3-way crossover study to compare the single-dose relative bioavailability of Cefprozil 250 mg/5 mL Oral suspension versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) following one 5 mL dose under fasting conditions
NCT00778739	Bioequivalence Study of Cefprozil 250 mg/ 5mL Powder For Oral Suspension Under Fed Conditions	Completed	Ranbaxy Laboratories Limited	N/A	2005-06-01	The study was conducted as an open-label, randomized, 2-way crossover study to compare the single-dose relative bioavailability of Cefprozil 250 mg/5 mL Oral suspension versus Cefzil TM Powder for Oral Suspension (250 mg/5 mL) following one 5 mL dose under fed conditions
NCT00778778	Bioequivalence Study of Cefprozil Tablets, USP 500 mg Under Fasting Conditions	Completed	Ranbaxy Laboratories Limited	N/A	2005-05-01	The objective of this study was to assess the single-dose relative bioavailability of Ranbaxy and Bristol-Myers Squibb Company (CEFZIL ®) 500 mg cefprozil tablets, under fasting conditions.
NCT00835354	Cefprozil for Oral Suspension 250 mg/5 mL, Non-fasting	Completed	Teva Pharmaceuticals USA	Phase 1	2004-05-01	The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under non-fasting conditions.
NCT00835614	Cefprozil for Oral Suspension 250 mg/5 mL, Fasting	Completed	Teva Pharmaceuticals USA	Phase 1	2004-04-01	The objective of this study is to compare the relative bioavailability of cefprozil for oral suspension 250 mg/5 mL (TEVA Pharmaceuticals USA) with that of CEFZIL® for Oral Suspension 250 mg/5 mL (Bristol-Myers Squibb) in healthy, non-smoking adults under fasting conditions.
NCT00840281	Cefprozil 500 mg Tablets Under Fasting Conditions	Completed	Teva Pharmaceuticals USA	Phase 1	2003-09-01	The objective of this study is to compare the relative bioavailability of cefprozil 500 mg tablets (Teva Pharmaceuticals USA) with that of Cefzil® 500 mg tablets (Bristol-Myers Squibb) in healthy, non-smoking adults under fasting conditions.

Clinical Trial Conditions for Cefprozil

Condition Name

Condition Name for Cefprozil
Intervention	Trials
Healthy	12
Osteomyelitis	1
Healthy Volunteers	1

Condition MeSH

Condition MeSH for Cefprozil
Intervention	Trials
Osteomyelitis	1

Clinical Trial Locations for Cefprozil

Trials by Country

Trials by Country for Cefprozil
Location	Trials
United States	7
Canada	4
China	1

Trials by US State

Trials by US State for Cefprozil
Location	Trials
Missouri	4
Texas	2
Kentucky	1

Clinical Trial Progress for Cefprozil

Clinical Trial Phase

Clinical Trial Phase for Cefprozil
Clinical Trial Phase	Trials
Phase 1	9
Phase 0	1
N/A	4

Clinical Trial Status

Clinical Trial Status for Cefprozil
Clinical Trial Phase	Trials
Completed	13
Not yet recruiting	1

Clinical Trial Sponsors for Cefprozil

Sponsor Name

Sponsor Name for Cefprozil
Sponsor	Trials
Ranbaxy Laboratories Limited	4
Sandoz	4
Teva Pharmaceuticals USA	4

Sponsor Type

Sponsor Type for Cefprozil
Sponsor	Trials
Industry	12
Other	4